Search ↗

Comparison

GHK-Cu vs Palmitoyl Tetrapeptide-7

GHK-Cu is healing & repair; Palmitoyl Tetrapeptide-7 is cosmetic & topical. They are compared here because they are frequently considered against each other, not because they act alike.

On published evidence alone, GHK-Cu is the better documented of the two (clinical trials). That is a statement about the state of the literature, not a recommendation.

GHK-Cu Palmitoyl Tetrapeptide-7
Class Healing & repair Cosmetic & topical
Evidence Clinical trials Preliminary human
Human trials ~15 ~4
Half-life ~30 minutes (systemic) Topical
Reported range 1-2 mg 1-4 mg
Frequency Daily topical, or subcutaneous in research protocols Applied topically 1-2x daily at 1-4% concentration
Routes Topical, Subcutaneous Topical
FDA approved No No
Research use only No No
Banned in sport No No
Studied for Skin repair and anti-ageing, Wound healing, Hair follicle stimulation Inflammatory skin ageing, Glycation reduction, Anti-ageing skincare
Reported side effects Local irritation, Transient redness, Injection-site reactions Mild local irritation

GHK-Cu

GHK is a tripeptide present in human plasma that declines markedly with age, and it binds copper(II) with high affinity to form GHK-Cu. The complex modulates expression of a large set of genes involved in tissue remodelling, stimulating collagen, elastin and glycosaminoglycan synthesis while influencing antioxidant and anti-inflammatory pathways. Its dermatological evidence is comparatively strong and includes controlled human trials; the systemic injectable use is far less supported.

Palmitoyl Tetrapeptide-7

Palmitoyl tetrapeptide-7 is the tetrapeptide GQPR, derived from an immunoglobulin fragment, conjugated to palmitic acid for skin penetration. It reduces production of interleukin-6 and other proinflammatory cytokines that rise with UV exposure and age, limiting the chronic low-grade inflammation that degrades dermal matrix. Matrixyl 3000 is a blend of palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7, which is why the two are rarely discussed separately. Original Matrixyl is a different peptide, palmitoyl pentapeptide-4.

GHK-Cu vs Palmitoyl Tetrapeptide-7: common questions

What is the difference between GHK-Cu and Palmitoyl Tetrapeptide-7?

GHK-Cu is healing & repair and Palmitoyl Tetrapeptide-7 is cosmetic & topical, so they act on different pathways. GHK-Cu: A naturally occurring copper-binding tripeptide with the strongest human evidence base of any compound in the healing group, mostly topical. Palmitoyl Tetrapeptide-7: An anti-inflammatory cosmetic peptide that targets glycation and cytokine-driven skin ageing, best known as one half of Matrixyl 3000.

Which has stronger evidence, GHK-Cu or Palmitoyl Tetrapeptide-7?

GHK-Cu has the stronger evidence base (clinical trials, about 15 human studies) compared with Palmitoyl Tetrapeptide-7 (preliminary human).

Are GHK-Cu and Palmitoyl Tetrapeptide-7 FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 139035031) ↗ · structure, identifiers, synonyms
  2. CAS Registry Number 89030-95-5 ↗ · chemical identity
  3. PubChem compound record (CID 10078408) ↗ · structure, identifiers, synonyms
  4. CAS Registry Number 221227-05-0 ↗ · chemical identity

Published literature

  1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.Int J Mol Sci 2018.PubMed 29986520 · doi:10.3390/ijms19071987
  2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.Biomed Res Int 2015.PubMed 26236730 · doi:10.1155/2015/648108
  3. Mayfield CK, Bolia IK, Feingold CL, et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
  4. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  5. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  6. Ogórek K, Nowak K, Wadych E, et al.. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?.Molecules 2025.PubMed 39795193 · doi:10.3390/molecules30010136
  7. Pickart L. The human tri-peptide GHK and tissue remodeling.J Biomater Sci Polym Ed 2008.PubMed 18644225 · doi:10.1163/156856208784909435
  8. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890
  9. Zhang B, Xu S, Liu M, et al.. The nucleoprotein of influenza A virus inhibits the innate immune response by inducing mitophagy.Autophagy 2023.PubMed 36588386 · doi:10.1080/15548627.2022.2162798
  10. Yang F, Zhang X, Wang H, et al.. Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream.Skin Res Technol 2024.PubMed 38932444 · doi:10.1111/srt.13790
  11. Navolotskaya EV. The second life of antibodies.Biochemistry (Mosc) 2014.PubMed 24512657 · doi:10.1134/S0006297914010015
  12. Yi L, Song J, Zhang Z, et al.. Palmitoyl-transferase 3 promotes mitochondrial antiviral signaling protein degradation by modulating its ubiquitination.Int J Biol Macromol 2025.PubMed 40300684 · doi:10.1016/j.ijbiomac.2025.143609
  13. Mohammed YH, Yamada M, Lin LL, et al.. Microneedle enhanced delivery of cosmeceutically relevant peptides in human skin.PLoS One 2014.PubMed 25033398 · doi:10.1371/journal.pone.0101956
  14. Veretennikova NI, Chipens GI, Nikiforovich GV, et al.. Rigin, another phagocytosis-stimulating tetrapeptide isolated from human IgG. Confirmations of a hypothesis.Int J Pept Protein Res 1981.PubMed 7309346 · doi:10.1111/j.1399-3011.1981.tb02011.x
  15. Meng W, Han SC, Li CC, et al.. Cytoplasmic Translocation of Nucleolar Protein NOP53 Promotes Viral Replication by Suppressing Host Defense.Viruses 2018.PubMed 29677136 · doi:10.3390/v10040208
  16. Porras M, Hernández D, Boto A. Antifungal Peptides with Unexpected Structure from a Library of Synthetic Analogs of Host-Defense Peptide Rigin.Int J Mol Sci 2025.PubMed 40076526 · doi:10.3390/ijms26051900

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.